Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
31 studies found for:    alnylam
Show Display Options
Rank Status Study
1 Available Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)
Conditions: TTR-mediated Amyloidosis;   Amyloidosis, Hereditary;   Amyloid Neuropathies, Familial;   Familial Amyloid Polyneuropathies;   Amyloid Neuropathies;   Amyloidosis, Hereditary, Transthyretin-Related
Intervention: Drug: patisiran (ALN-TTR02)
2 Completed Intranasal ALN-RSV01 Administered to Adult Volunteers Experimentally Inoculated With Respiratory Syncytial Virus
Condition: Respiratory Syncytial Virus Infections
Intervention: Drug: ALN-RSV01
3 Recruiting A Study of ALN-HBV in Healthy Adult Volunteers and Non-cirrhotic Patients With Chronic Hepatitis B Virus (HBV) Infection
Conditions: Hepatitis B;   Chronic Hepatitis B;   Hepatitis B, Chronic;   Hepatitis B Infection;   HBV
Interventions: Drug: ALN-HBV;   Drug: Sterile Normal Saline (0.9% NaCl)
4 Recruiting A Safety and Tolerability Study of an Investigational Drug, ALN-TTRSC02, in Healthy Subjects
Condition: Transthyretin-mediated Amyloidosis (ATTR Amyloidosis)
Interventions: Drug: ALN-TTRSC02;   Drug: Sterile Normal Saline (0.9% NaCl)
5 Recruiting Study of ALN-GO1 in Healthy Adult Subjects and Patients With Primary Hyperoxaluria Type 1
Condition: Primary Hyperoxaluria Type 1 (PH1)
Interventions: Drug: ALN-GO1;   Drug: Sterile Normal Saline (0.9% NaCl)
6 Recruiting An Open-label Extension Study of an Investigational Drug, ALN-AT3SC, in Patients With Moderate or Severe Hemophilia A or B
Conditions: Hemophilia A;   Hemophilia B
Intervention: Drug: ALN-AT3SC
7 Recruiting A Phase 1 Study of ALN-AS1 in Patients With Acute Intermittent Porphyria (AIP)
Condition: Acute Intermittent Porphyria
Interventions: Drug: ALN-AS1;   Drug: Sterile Normal Saline (0.9% NaCl)
8 Recruiting A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients
Conditions: Hemophilia A;   Hemophilia B
Interventions: Drug: ALN-AT3SC;   Drug: Sterile Normal Saline (0.9% NaCl)
9 Enrolling by invitation A Study to Evaluate Long-term Safety and Clinical Activity of ALN-AS1 in Patient With Acute Intermittent Porphyria (AIP)
Condition: Acute Intermittent Porphyria
Intervention: Drug: ALN-AS1
10 Active, not recruiting The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant
Conditions: Transthyretin (TTR)-Mediated Amyloidosis;   Familial Amyloidotic Polyneuropathy (FAP);   ATTR Amyloidosis;   Familial Amyloid Neuropathies
Intervention: Drug: Revusiran (ALN-TTRSC)
11 Enrolling by invitation The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Who Have Already Been Treated With ALN-TTR02 (Patisiran)
Condition: Amyloidosis
Intervention: Drug: Patisiran (ALN-TTR02)
12 Active, not recruiting A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease
Condition: Antitrypsin Deficiency Liver Disease
Interventions: Drug: ALN-AAT;   Drug: Sterile Normal Saline (0.9% NaCl)
13 Active, not recruiting A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH
Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions: Drug: ALN-CC5;   Drug: Sterile Normal Saline (0.9% NaCl)
14 Active, not recruiting ENDEAVOUR: Phase 3 Multicenter Study of Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC)
Conditions: Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC);   Amyloidosis, Hereditary;   Amyloid Neuropathies, Familial;   Amyloid Neuropathies;   Amyloidosis, Hereditary, Transthyretin-Related;   Familial Transthyretin Cardiac Amyloidosis
Interventions: Drug: Revusiran (ALN-TTRSC);   Drug: Sterile Normal Saline (0.9% NaCl)
15 Completed A Phase 1 Study of an Investigational Drug, ALN-PCSSC, in Subjects With Elevated Low Density Lipoprotein Cholesterol (LDL-C)
Condition: Hypercholesterolemia
Interventions: Drug: ALN-PCSSC;   Drug: Sterile Normal Saline (0.9% NaCl)
16 Active, not recruiting A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
Condition: TTR-mediated Amyloidosis
Intervention: Drug: Revusiran (ALN-TTRSC)
17 Completed DISCOVERY: A Study Examining the Prevalence of TTR Mutations in Subjects Suspected of Having Cardiac Amyloidosis
Condition: Familial Amyloidotic Cardiomyopathy (FAC)
Intervention:
18 Active, not recruiting EXPLORE: A Natural History Study of Acute Hepatic Porphyria (AHP)
Condition: Acute Hepatic Porphyria
Intervention:
19 Completed A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers
Condition: Transthyretin (TTR)-Mediated Amyloidosis
Interventions: Drug: patisiran (ALN-TTR02);   Drug: Sterile Normal Saline (0.9% NaCl)
20 Completed Phase 2 Study to Evaluate ALN-TTRSC (Revusiran) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
Condition: TTR-mediated Amyloidosis
Intervention: Drug: ALN-TTRSC (revusiran) for subcutaneous administration

   Previous Page Studies Shown (1-20) Next Page (21-31) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.